High Throughput Screening & Process Development – how small can we get?Biotech industry has adopted HT screening in micro well plates as process development tools but still the major question remains on how the process can be optimised, so that it is representative of the large scale. Conversely what are the criteria for scaling-up the process developed at the microscale to large scale systems? Meanwhile technologies of even smaller dimensions such as microfluidic devices, lab-on-a chip approaches and HTPD on the nanoscale are discussed as state of the art for process development in the biotech community.
Successful application of HT systems for process development depends on the right choice of technology in combination with Design of experiment strategies or mechanistic modelling and statistical evaluation of the obtained data.
Scientific Comitee:Ana Azvedo, IST; Astrid Dürauer, BOKU Vienna; Karol Lacki, Avitide; Marcel Ottens, TU Delft; Jennifer Pollard, Merck &Co
The symposium will focus on:
- • Lab on a chip approach for process development in up and downstream processing
- • Application of DoE and statistical evaluation of large data
- • Microfluidic devices for up and downstream processing and their limitations
- • Nanoscale devices to predict process data
- • Microscale methods for process development in up and downstream processing – case studies, commercial systems
- • Scale up / down rules for process development in up and downstream processing and their limitations
Questions to be addressed:
- • Are there still open questions to be addressed?
- • Can we predict production scale processes from microscale experiments?
- • How small is large enough?
- • How should we generate HT data to get the best out of it?
- • Which a priori information is necessary to design experiments?
Renowned speakers from academia and industry will give keynote lectures on the topic and will be part of a round table discussion. Researchers from academia and industry will be invited for presentations. Participants are invited to submit their work for flash presentations and poster session.
A site visit at Boehringer Ingelheim RCV is organized on Tuesday morning (max. 25 participants, first come first serve) including a short introduction of the company and a guided tour to the automation lab at the Process Bioscience Division where a HT platform for process development of E.coli derived products has been set up in collaboration with BOKU Vienna.
A get together will be organized at a typical Viennese Heurigen.
Who should attend?
- • All others working in the field of HTPD from industry and academia are highly welcome
- • PhD students in fields of biotechnology, biochemical engineering, chemicals engineering
Sunday, September 12th, 2021
|From 3:00 pm||Registration|
|4:15 pm||Keynote I – Lessons learned in building high‐throughput process development capabilities,
Jennifer Pollard, Merck; USA
|5:00 pm||Keynote II – Design of Experiments and AI: Friends or enemies for mechanistic modelling?
Shuichi Yamamoto, Yamaguchi University, Japan
|6 pm to 8 pm||Welcome Reception|
Monday, September 13th, 2021
|Session I: Engineering Fundamentals for Scaling|
|9:05||Can we directly go from microscale to industrial scale – what are the challenges we face?
Astrid Dürauer, BOKU Vienna, Austria
|9:30||What can we learn from proteins for process development of the new formats?
Alois Jungbauer, BOKU Vienna, Austria
|9:55||Automated microscale processing: fundamentals and application to biopharmaceuticals production,
Martina Micheletti, University College London, UK
|10:20 - 10:40||Coffee Break|
|Session II: Bioprocess Development|
|10:45||General considerations on scaling and high throughput aspects in Upstream process development,
Gerald Striedner, BOKU Vienna, Austria
|11:15||Challenges of establishing a fermentation development platform in an industrial environment,
Sandra Abad, Boehringer-Ingelheim RCV, Austria
|11:40||Moving towards fully autonomous model-based high-throughput bioprocess development and clone discrimination,
Peter Neubauer, TU Berlin, Germany
|Session III: Downstream Processing|
|1:00||The real world of preparative protein chromatography: multi-component adsorption,
Rainer Hahn, BOKU Vienna, Austria
|1:25||Integrated process modelling and machine learning applied to high throughput process development,
Cécile Brocard, Boehringer-Ingelheim RCV, Austria
|1:50||Scalability of pre-packed preparative chromatography columns with different diameters and lengths - considering extra column effects,
Susanne Schweiger, R&D Croma-Pharma, Austria
|2:15 - 2:45||Coffee Break|
|Session IV: 5`Flash presentations (tba based on the submissions)|
|3:15 – 4:45||Poster Session|
|Session V: Keynote and Round Table Discussion|
|4:45|| 20 years of HTPD - lessons learned and future directions,
Karol Lacki, Avitide, USA
|5:15||Round Table Discussion “Quo vadis HTPD – what do we know, what is still missing”
Participants: Cécile Brocard, Karol Lacki, Jennifer Pollard, Shuichi Yamamoto
Moderation: Marcel Ottens, Astrid Dürauer
|7 pm||Dinner at Heurigen|
Tuesday, September 14th, 2021
|Site Visit Boehringer-Ingelheim RCV|
|9 to 11:30 am||Site Visit Boehringer-Ingelheim RCV (max.25 participants, registrations mandatory), Individual travel to and from BI- RCV, Meeting point: 8:45 am Porter ́s Lodge, "Gate Mitte", Belghofergasse 12, 1120 Vienna; Bring your photo identification!|
|12:00 – 1:00||Lunch at BOKU|
|Topic III: Microfluidics|
|1:00||Nano Scale HTPD,
Marcel Ottens, TU Delft, NL
|1:25||How to fasten chromatography process development using a microfluidic lab-on-a-chip platform,
Ana Azedvedo, Instituto Superior Técnico, Lisbon, Portugal
|1:50||From Small Molecules to Cell & Gene Therapy: A Journey in Bioprocess
Nicolas Szita, University College London, UK
|2:15||Flow Biocatalysis: Challenges and Opportunities for Bioprocessing,
Marco Marques, UCL, University College London, UK
|Session VII: Big data and Modelling|
|3:00||Statistical Models in Up- and Downstream Processing – their merits, limitations and realization with R,
Michael Melcher, BOKU Vienna, Austria
|3:25||The beauty of mechanistic models,
Bernt Nilsson, Lund University, Sweden
|3:50||Advanced machine learning for bioprocess development - How hybrid models can change the perspective,
Mark Dürkop, Novasign, Vienna, Austria
|4:15||How can computational fluid dynamics help us with scaling challenges? N.N.|
|4:40||Closing Remarks & End of Symposium|
Download Programme (PDF)